aTyr Pharma laid off 60% of its workforce as it conserves resources for a second shot at Phase 3 success in a lung disease program. The report indicates the company is taking cost-reduction steps to extend runway ahead of renewed late-stage development. The move signals the high cash-burn reality of late-stage risk when clinical outcomes have not met expectations. It also underscores how management may prioritize a single, most-promising pathway rather than broad portfolio spending. For the sector, the restructuring is likely to affect partner confidence, hiring plans, and the cadence of program updates leading into the next Phase 3 readout strategy.